← All trials
NCT04356846
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2020
- Primary completion
- Apr 1, 2022
- Completion date
- Dec 1, 2022
- First posted
- Apr 22, 2020
- Last posted
- Apr 22, 2020
- Enrollment
- 74
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Nanjing Medical UniversityLead sponsor
- Newave Pharmaceutical IncCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.